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Aberrant CXCR4 activity has been implicated in lymphoma pathogenesis, disease progression, and resistance to therapies. Using a
mouse model with a gain-of-function CXCR4 mutation (CXCR4C1013G) that hyperactivates CXCR4 signaling, we identified CXCR4 as a
crucial activator of multiple key oncogenic pathways. CXCR4 hyperactivation resulted in an expansion of transitional B1
lymphocytes, which represent the precursors of chronic lymphocytic leukemia (CLL). Indeed, CXCR4 hyperactivation led to a
significant acceleration of disease onset and a more aggressive phenotype in the murine Eµ-TCL1 CLL model. Hyperactivated
CXCR4 signaling cooperated with TCL1 to cause a distinct oncogenic transcriptional program in B cells, characterized by PLK1/
FOXM1-associated pathways. In accordance, Eµ-TCL1;CXCR4C1013G B cells enriched a transcriptional signature from patients with
Richter’s syndrome, an aggressive transformation of CLL. Notably, MYC activation in aggressive lymphoma was associated with
increased CXCR4 expression. In line with this finding, additional hyperactive CXCR4 signaling in the Eµ-Myc mouse, a model of




CXCR4 is a G-protein-coupled receptor regulating hematopoietic
stem cell homeostasis, myelopoiesis, lymphopoiesis, and homing
of immune cells toward its ligand C-X-C motif chemokine 12
(CXCL12) [1–3]. CXCL12 binding induces a multitude of G-protein-
dependent and -independent signaling pathways including PI3K/
AKT, MAPK/ERK, and PLC/Ca2+ signaling [4]. CXCR4 is phosphory-
lated at the C-terminus and rapidly internalized after binding of
CXCL12 [5]. Truncating mutations affecting the C-terminus lead to
increased activity of CXCR4 signaling in response to its ligand by
impairing receptor desensitization and internalization without
impairing receptor expression level [6–8], which has been
modeled in mice [9].
B cells in particular are highly dependent on the interaction of
CXCR4 and its ligand CXCL12 at multiple stages during the
germinal center reaction [10]. Molecularly targeted imaging
studies have revealed enhanced CXCR4 expression in various
B-cell non-Hodgkin lymphomas [11–13]. CXCR4 is of particular
interest in chronic lymphocytic leukemia (CLL) and diffuse large
B-cell lymphoma (DLBCL), having been associated with adverse
prognosis in both diseases [14, 15]. CXCR4 is overexpressed in CLL
patients and involved in interactions of CLL cells with their
microenvironment, specifically the protection from apoptosis by
the provided ligand CXCL12 [16–18]. In DLBCL, CXCR4 expression
correlates with bone marrow infiltration [19] and has been implied
in mediating resistance to B-cell receptor and PI3K inhibitors [20].
Genetically engineered mouse models for CLL and aggressive
B-cell lymphoma, specifically the Eµ-TCL1mouse model of CLL [21]
and the Eµ-Myc mouse model of aggressive MYC-induced B-cell
lymphoma [22], are essential for studying leukemia/lymphoma
pathogenesis and complex biological systems like chemokine
receptor pathways in B-cell pathobiology. The Eµ-TCL1 mouse, in
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which B-cell-directed TCL1 expression drives development of a
CLL-like disease, is the most commonly used model for high-risk
CLL and has been extensively used for mechanistically assessing
oncogenes and tumor suppressors in CLL [23, 24]. By using the
Eµ-TCL1model, Chen et al. showed that downregulation of surface
CXCR4 expression and inhibition of CXCR4 downstream signaling
in CLL cells can be observed upon treatment with the clinically
approved Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib [25].
CXCR4 inhibitors are currently under investigation in clinical trials
in CLL [26].
Mutations of CXCR4 are present in DLBCL patients, but no
functional studies have been performed to further inquire their
function in this disease [27, 28]. Intriguingly, rare germline
mutations in CXCR4 have been found in CLL patients with familial
clustering [29] and mutations in regulatory regions of CXCR4 were
discovered in biopsies of CLL with aggressive transformation
(Richter’s syndrome) [30]. It is however not resolved if and how
they affect CXCR4 pathway activity and disease progression.
Despite a plethora of evidence linking CXCR4 to the pathogenesis
of CLL and DLBCL, it is unknown if and how enhancing CXCR4
pathway activity can alter the course of B-cell lymphoproliferation,
and B-cell leukemia/ lymphoma development and progression.
In this study, we employed the Eµ-TCL1 and Eµ-Myc mouse
models to interrogate the role of hyperactivated CXCR4 signaling
in B-cell lymphoproliferation and B-cell leukemia/lymphoma
pathogenesis. CXCR4 hyperactivation was achieved by a mouse
model harboring CXCR4C1013G, a mutation resulting in a truncated
C-terminus missing phosphorylation sites for CXCR4 internaliza-
tion and consequently enhanced downstream signaling [9]. This
mutation is characteristic for WHIM-syndrome (warts, hypogam-
maglobulinemia, infections, myelokathexis) patients and allows
the investigation of CXCR4 hyperactivation on B-cell lymphopro-
liferation and lymphoma development.
MATERIAL AND METHODS
Animal experiments
Genotyping was performed as previously described [9, 21, 31]. All analyses
included heterozygous female and male animals on a C57BL/6J back-
ground. Animal caretakers, but not researchers performing experiments,
were blinded for genotypes. Mice were allocated to groups based on
genotype, thus no randomization was performed. All animal experiments
were performed in accordance with Federation of European Laboratory
Animal Science Associations guidelines and with permission of the
respective authorities (Regierung von Oberbayern, Munich, Germany &
Landesamt für Gesundheit und Soziales, Berlin, Germany).
Flow cytometry
Staining was performed in PBS (ThermoFisher Scientific, Waltham, MA)
containing 0.5% BSA (Carl Roth GmbH, Karlsruhe, Germany). To distinguish
live from dead, cells were stained with PI, DAPI, or Invitrogen Fixable Aqua
Dead Cell Stain Kit (ThermoFisher Scientific, Waltham, MA). Data analysis
was done with FlowJo™ Version 10.6.0 (FlowJo, Ashland, OR). An extensive
list of all fluorescently labeled antibodies can be found in Supplementary
Table T1. Gating strategies are depicted in Supplementary Fig. S1.
Histopathological analysis
Tissue samples were fixed in 4% formaldehyde for 48 h, paraffin
embedded, sectioned, and stained using H&E. Samples of bone marrow
were decalcified by incubating for 14 days with Osteosoft® (Sigma-Aldrich,
Saint Louis, MI) after fixation.
Immunohistochemistry
Immunohistochemistry on murine tissues was performed on an automated
immunostainer (Ventana Medical Systems Inc., Oro Valley, AZ) according to
the company’s protocols for open procedures with slight modifications.
Appropriate positive and negative controls were used to confirm the
adequacy of the staining. The histologic samples were analyzed by an
experienced pathologist (L. Quintanilla-Martinez). Photomicrographic
images were acquired with an Axioskop 2 plus Zeiss microscope equipped
with a Jenoptik (Laser Optik System, Jena, Germany) ProgRes C10 plus
camera and software. Objectives Plan-Neofluar used were as follows: 1.25/
0,035, 2.5×/0.075, 10×/0.30, 20×/0.50, and 40×/0.75. Final image prepara-
tion was performed with Adobe Photoshop CS6 (Adobe Inc., San José, CA).
RNA sequencing
B cells from spleen and bone marrow of WT, CXCR4C1013G, Eµ-TCL1, and
Eµ-TCL1;CXCR4C1013G were isolated with CD19 directed magnetic beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Only RNA samples with an
RNA integrity number (RIN) > 7 were used for RNA sequencing. RIN was
determined using Agilent RNA 6000 Nano Kit (# 5067-1513, Agilent, Santa
Clara, CA) and the Agilent 2100 Expert software (version B.02.10.SI764).
Library preparation and single-end sequencing was subsequently
performed by Novogene (UK) (Cambridge, UK) on a HiSeq2500 (Illumina,
San Diego, CA) with a sequencing depth of more than 20M reads/sample.
Fastq files were subsequently mapped to the murine reference genome
GRCm38 with STAR.
Reads and transcripts per million (TPM) were estimated for each
transcript using the transcript sequences from the GENCODE Release 25
(GRCm38) and the Salmon software (v1.3.0). Counts and TPM were
summarized at the gene level by summing up the transcript values for
each corresponding gene. Bioinformatic analyses are described in the
Supplementary methods section.
Immunoblot analysis
Protein extracts were prepared by incubating cell pellets in lysis buffer (50
mM Hepes, 150mM NaCl, 1mM EDTA, 2.5mM EGTA and 0.1% Tween)
supplemented with NaF, PMSF, and NaVO4 followed by sonification. Protein
lysates were fractioned on SDS PAGE gels, transferred to Immobilon-P
(Millipore, Burlington, MA) membranes and incubated with specific
antibodies, and developed with Chemostar PC ECL & Fluorescence Imager
(Intas Science Imaging, Göttingen, Germany). A list of antibodies used can be
found in Supplementary Table T1. Quantification of protein expression levels
was performed using ImageJ software (https://imagej.nih.gov/ij).
Migration assay
Splenocytes were resuspended in RPMI-medium with or without 1 µM
AMD3100 (Sigma-Aldrich, Saint Louis, MI). Cells were then loaded onto a
Corning® Transwell® 96-well plate with 5 µm pore size. (Corning Inc.,
Corning, NY) with the other side of the membrane containing medium
with/without 50 nM of CXCL12 (Peprotech, Rocky Hill, CT). Transwell®
plates were incubated for 4 h at 37 °C. Migration of cells to the lower wells
was measured using CountBright™ Absolute Counting Beads (Thermo-
Fisher Scientific, Waltham, MA).
Statistics
Statistical analyses were performed using GraphPad Prism Version 9.0.
(GraphPad Software, La Jolla, CA). Error bars represent standard deviation. Bar
graphs represent the mean. In animal experiments, a single data point
represents an individual mouse. No sample size calculations were performed.
Data from at least three mice per group were reported. In survival analyses,
mice were excluded when the cause of death was not transgene-related (e.g.
fighting, birth complications). A two-tailed Student’s t test was used to
compare quantitative data between 2 independent samples. When
comparing three or more groups, a one-way ANOVA with Tukey correction
for multiple comparisons was used to compare group means. Survival data
were compared using a logrank (Mantel–Cox) test. Results with a P value of
less than 0.05 were considered significant.
RESULTS
CXCR4 hyperactivation promotes a distinct transcriptional
signature in non-malignant B cells
To investigate the consequences of hyperactivated CXCR4 on
intrinsic signaling in B cells, we purified CD19+ B cells from
CXCR4+/C1013G mice (CXCR4C1013G from here on) and wild-type control
mice (WT from here on) (Fig. 1a). To confirm enhanced CXCR4 signal-
ing activity in CXCR4C1013G B cells, we performed immunoblotting for
phosphorylation of the well-established downstream effector kinases
ERK and AKT. As expected, both ERK and AKT phosphorylation were















readily increased upon stimulation with CXCL12 compared to control
B cells (Fig. 1b, c). To get a more comprehensive understanding to
which extent CXCR4 hyperactivation shapes the transcriptional
landscape, we performed whole-transcriptome profiling of CD19+ B
cells from CXCR4C1013G and WT mice. CXCR4C1013G B cells exhibited a
set of 199 differentially expressed genes (DEGs, protein coding, padj
< 0.05; logFC > 0.5 or <−0.5) compared to WT controls (Fig. 1d).
Among upregulated genes in B cells with hyperactivated
CXCR4 signaling, we identified genes involved in chemokine
signaling, migration and adhesion (Ccr1, Cxcl1, Cxcl2, Igfn1, Cntn2,
Jaml), NOTCH signaling (Sorbs2), inflammation, and cytokine
signaling (Il9r, Il7r, Csf2rb, Trem1), B-cell maturation (Rag1, Rag2),
plasma cell differentiation and proliferation (Prdm1), metabolism
(Pdk1) and cell cycle progression (Nek6). Of note, the CXCL12-binding
receptor Ackr3 (encoding CXCR7), which is known to form
heterodimers with CXCR4 and is dysregulated in inflammatory
diseases and cancers [32], was upregulated. From these significantly
regulated 199 DEGs in CXCR4C1013G vs. WT, we generated a gene set
defining the transcriptional profile of hyperactivated CXCR4 signaling
(CXCR4a) in B cells (Supplementary Table T2). Subsequently, to test if
CXCR4a represents a meaningful biological readout for enhanced
CXCR4 signaling, we performed GSEA analysis with well-established
published transcriptional signatures. We found that B cells of
CXCR4C1013G mice enriched chemokine receptor signaling, inflam-
matory response and cytokine signaling pathways (Fig. 1e). Fully in
line with the implication of CXCR4 in B-cell cancers, we found cancer-
relevant pathways such as Kras signaling and glycolysis as well as
depletion of DNA repair pathways in CXCR4C1013G B cells (Fig. 1e).
Thus, we here defined the transcriptional signature of
hyperactivated CXCR4 signaling in B cells. Our data demonstrate
the complexity of the transcriptional consequences of CXCR4
activation and represent a tool to assess activity of the CXCR4
pathway. Moreover, we found that enhancing CXCR4 signaling
activity leads to the enrichment of several cancer-associated
pathways, revealing that hyperactivated CXCR4 signaling might
thereby predispose B cells for malignant transformation.
Enhanced CXCR4 signaling cooperatively accelerates
lymphoproliferation and promotes disease aggressiveness
with TCL1
CXCR4 plays an essential role in B-cell biology and is highly
expressed in B cells as compared to all other cell types
(Supplementary Fig. S2a). Considering that CXCR4 hyperactivation
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Fig. 1 Identification of a transcriptional signature of hyperactivated CXCR4 signaling. a Illustration of the CXCR4C1013G truncating mutation
and outline of experimental setup for immunoblotting and RNA sequencing of splenic and bone marrow B cells. b Representative image of
immunoblotting for AKT, pAKT (Ser473), ERK, pERK (Thr202/Tyr204), and Actin of CD19+ B cells treated with/without 50 nM CXCL12 and/or 10 µM
CXCR4 inhibitor AMD3100 (AMD) (WT, n= 3; CXCR4C1013G, n= 3). c Relative pAKT to AKT and pERK to ERK protein expression by immunoblotting of
WT and CXCR4C1013G CD19+ B cells treated with/without 50 nM CXCL12 and/or 10 µM CXCR4 inhibitor AMD3100 (WT, n= 3; CXCR4C1013G, n= 3).
d Volcano plot showing differentially expressed genes (DEG) of CXCR4C1013G vs. WT CD19+ B cells (WT, n= 5; CXCR4C1013G, n= 5). e Gene set
enrichment analysis (GSEA) of CXCR4C1013G vs. WT CD19+ B cells showing normalized enrichment scores (NES) and false discovery rates (FDR) for
curated gene sets listed in MsigDB [63, 64] of CXCR4C1013G compared to WT CD19+ B cells. Statistical analyses were performed with one-way
ANOVA with Tukey correction for multiple comparisons, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars indicate standard deviation (SD).
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confirming the association of elevated CXCR4 expression with
adverse prognosis in CLL patients (Supplementary Fig. S2b), we
sought to directly investigate the effect of enhanced
CXCR4 signaling on B-cell lymphoproliferation and CLL develop-
ment in vivo. We thus chose the Eµ-TCL1 model of B-cell
tumorigenesis, where the T-cell lymphoma/leukemia 1 (TCL1)
transgene is targeted to B cells [21] and intercrossed it with
CXCR4C1013G mice (Fig. 2a). As expected from previous experiments
[21], Eµ-TCL1 mice developed a gradually progressing B-cell
lymphoproliferation with a CD19+CD5+/CD19+B220dim immu-
nophenotype (Fig. 2b, Supplementary Fig. S3a). We found that in
Eµ-TCL1;CXCR4C1013G mice, this lymphoproliferation started earlier
as compared to Eµ-TCL1, indicated by an increased bone marrow
and splenic infiltration of CD19+CD5+/CD19+B220dim cells
(Fig. 2b, Supplementary Fig. S3a) and increased spleen weight
starting at 5–6 months of age (Fig. 2c). This finding was supported
by histopathological analysis, where Eµ-TCl1 mice exhibited
enlarged spleens with moderate preservation of the white pulp
and clear expansion of the red pulp, which was incipiently
infiltrated by B cells, while in Eµ-TCL1;CXCR4C1013G mice the white
pulp was atrophic with expansion of the red pulp and
morphologically more pronounced infiltration (Fig. 2d, Supple-
mentary Fig. S3b). In the bone marrow, the infiltration was
significantly increased in the Eµ-TCL1;CXCR4C1013G compared to Eµ-
TCL1 (Fig. 2d, Supplementary Fig. S3b). B220 expression at this
stage was significantly lower in Eµ-TCL1;CXCR4C1013G compared to
Eµ-TCL1 CD19+CD5+ cells (Supplementary Fig. S3c). Importantly,
the frequency of CD3e+, CD4+, and CD8+ T cells in spleens of Eµ-
TCL1 and Eµ-TCL1;CXCR4C1013G did not differ significantly (Supple-
mentary Fig. S3d). In summary, TCL1 mediated B-cell lymphopro-
liferation is accelerated by enhanced CXCR4 signaling.
To investigate if CXCR4 hyperactivation alone creates a predisposi-
tion favoring TCL1-driven B-cell proliferation and CLL development,
we performed B-cell immunophenotyping of CXCR4C1013G mice,
focusing on transitional B cells and the population of CD19+/
B220dim/CD5+ B1 B cells. A potential mechanism of CLL develop-
ment in the Eµ-TCL1 mouse involves accumulation of autoreactive B
cells in the transitional T1 population, giving rise to CD19+/B220dim
and, to limit autoreactivity, CD5+ B cells, which eventually progress to
lethal B-cell leukemia [33–35]. Indeed, in spleens of CXCR4C1013G mice,
T1 B cells were increased, and T2 B cells were decreased (Fig. 2e). The
CD19+B220dim/CD5+ B1 B-cell population known from Eµ-TCL1
mice was already significantly increased in bone marrow and spleen
of CXCR4C1013G mice compared to WT littermate controls (Fig. 2f,
Supplementary Fig. S3e, f), which was in line with the observed
increase in T1 B cells in Eµ-TCL1;CXCR4C1013G. These findings indicate
an inherent susceptibility of B cells with CXCR4 hyperactivation for
aberrant B-cell lymphoproliferation, which is further enhanced in
cooperation with TCL1.
Next, we tested in a cohort of Eµ-TCL1 vs. Eµ-TCL1;CXCR4C1013G
mice how CXCR4 hyperactivation impacts disease onset. We found
that CXCR4 activation profoundly accelerates development of
symptomatic CLL requiring euthanasia in collaboration with TCL1.
Enhancing CXCR4 activity reduced the median survival by
~100 days compared to TCL1 alone (Fig. 3a). Importantly, this
finding was accompanied by enhanced nodal dissemination of
CLL, as indicated by the development of pronounced lymphade-
nopathy, which was not observed in Eµ-TCL1 mice (Fig. 3b,
Supplementary Fig. S4a). The immunophenotype and infiltration
with T cells remained unchanged in mice with symptomatic CLL
requiring euthanasia, as seen in pre-malignant mice, and spleen
and liver weights were similar when mice presented with
symptoms (Supplementary Figs S4b, c). Histopathology of mice
presenting with symptomatic CLL showed extensive infiltration of
the red pulp in both genotypes, with complete atrophy of the
white pulp in spleens. Visually evaluated by an experienced
hematopathologist, the bone marrow of Eµ-TCL1;CXCR4C1013G mice
displayed a diffuse infiltration pattern, compared to a more focal
infiltration pattern in Eµ-TCL1 controls (Fig. 3c, Supplementary
Fig. S4d). Strikingly, three out of seven Eµ-TCL1;CXCR4C1013G mice
exhibited hallmark features of aggressive B-cell lymphoma in
affected lymph nodes, morphologically resembling DLBCL-type
Richter’s transformation occurring in CLL patients. Accordingly,
lymphoma cells were larger than typical Eµ-TCL CLL cells,
infiltrated surrounding muscle and adipose tissue, and showed
higher expression of the proliferation marker Ki67 (Fig. 3d and
Supplementary Fig. S4e). Furthermore, three Eµ-TCL1;CXCR4C1013G
mice presented with histiocytic sarcoma, a rare complication also
in CLL patients, in which CLL cells transform into malignant
histiocytes [36] (Supplementary Fig. S4f).
To investigate if the effects of CXCR4 hyperactivation on B-cell
leukemia and lymphoma development and dissemination are B
cell intrinsic, we isolated splenocytes of pre-malignant animals
and assessed their migratory capacity in response to CXCL12
ex vivo. When assessing the subgroup of CD19+CD5+ cells, of
which Eµ-TCL1 tumors evolve, we could see significantly higher
migratory capacity specifically in Eµ-TCL1;CXCR4C1013G compared
to WT, Eµ-TCL1 and even CXCR4C1013G. Strikingly, no increased
migratory potential compared to CXCR4C1013G could be seen in
bulk splenocytes and CD5+ T cells, suggesting a direct B-cell-
intrinsic collaboration of TCL1 and CXCR4 hyperactivation (Fig. 3e).
Thus, we provide first experimental in vivo evidence that CXCR4
hyperactivation supports and accelerates lymphoproliferation and
CLL development in a susceptible genetic background, favoring
development of a highly proliferative, nodally disseminating
cancer with features of aggressive B-cell lymphoma or histiocytic
sarcoma in a subset of Eµ-TCL1;CXCR4C1013G mice.
Hyperactivated CXCR4 is a hallmark of aggressive lymphoma
biology
Next, we sought to determine if enhanced CXCR4 activity would
also result in a more accelerated lymphoma biology in a model of
aggressive lymphoma. Analyzing published datasets of DLBCL,
the most common aggressive B-cell lymphoma [27, 28, 37], we
confirmed that elevated CXCR4 expression correlates with adverse
prognosis (Supplementary Fig. S5a) and that CXCR4 mutations
are present, but rare, in DLBCL patients (Supplementary Figure S5b
and Supplementary Table T3). To functionally investigate the role
of CXCR4 hyperactivation in the context of aggressive B-cell
lymphoma, we chose the Eµ-Myc mouse model, which is
characterized by B-cell-targeted overexpression of MYC, leading
to MYC-driven aggressive B-cell lymphoma [31]. This model
reflects some of the features of MYC-dependent B-cell biology,
which is activated in DLBCL and Burkitt’s lymphoma. To
investigate how additional CXCR4 activity alters MYC-induced
lymphomagenesis, we intercrossed CXCR4C1013G with Eµ-Myc mice
(Fig. 4a). In young 1-month-old mice, we found similarly elevated
white blood cell counts in Eµ-Myc and Eµ-Myc;CXCR4C1013G
indicating tumor development in both cohorts (Supplementary
Fig. S6a). Strikingly, even at this very early time point, we could
already discover increased spleen weights compared to age-
matched Eµ-Myc and control animals (Fig. 4b). This finding was
complimented by histopathology, showing that the spleens of Eµ-
Myc;CXCR4C1013 mice had a more pronounced infiltration of pre-
malignant B cells (Fig. 4c and Supplementary Fig. S6b) very early
on. In mice with manifest lymphoma, the Eµ-Myc;CXCR4C1013G
genotype was associated with a more aggressive presentation as
demonstrated by larger spleens and higher bone marrow cell
count (Fig. 4d, e). Although Eµ-Myc;CXCR4C1013G displayed features
indicative of a more aggressive lymphoma phenotype, median
survival did not differ compared to Eµ-Myc controls (Fig. 4f). In
mice with lymphoma requiring euthanasia, leukocyte counts and
immunophenotype of tumors were comparable between both
cohorts (Supplementary Fig. S6c, d). Histopathology confirmed the
aforementioned findings of the pre-malignant cohorts, and
revealed that Eµ-Myc;CXCR4C1013G mice presented with a higher
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Fig. 2 CXCR4 hyperactivation blocks B-cell differentiation leading to expansion of pre-malignant B cells in cooperation with TCL1.
a Outline of breeding scheme of CXCR4C1013G and Eµ-TCL1mice to generate double-transgenic Eµ-TCL1;CXCR4C1013G mice. b Representative contour
plots of splenic CD19+CD5+ cells by flow cytometry in 5–6-month-old animals and quantification of splenic and bone marrow CD19+CD5+ cells
(Eµ-TCL1, n= 4; Eµ-TCL1;CXCR4C1013G, n= 5). c Spleen weight of 5–6-month-old mice (Eµ-TCL1, n= 4; Eµ-TCL1;CXCR4C1013G, n= 6). d Representative
images of H&E and immunohistochemistry of 5–6-month-old Eµ-TCL1 and Eµ-TCL1;CXCR4C1013G mice (scale bars spleen: overview= 1mm, detailed
images: 200 µm, scale bars bone marrow: overview= 200 µm, detailed images= 20 µm). e Quantification and representative contour plots of
splenic T1 (IgM+CD23−) and T2 (IgM+CD23+) cells gated on B220+CD93+ B cells by flow cytometry of 3-month-old animals (WT, n= 5;
CXCR4C1013G, n= 5). f Quantification and representative contour plots of splenic and bone marrow CD19+B220dimCD5+ B1 cells of 3-month-old
animals (WT, n= 5; CXCR4C1013G, n= 5). Statistical analyses were performed with Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars
indicate standard deviation (SD).
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tendency toward extranodal disease, e.g., hepatic infiltration by
lymphoma cells, further indicating a more invasive, extranodal
phenotype of CXCR4 hyperactivated lymphoma (Fig. 4g and
Supplementary Fig. S6e).
To investigate CXCR4 expression in Eµ-Myc mice as compared to
WT and Eµ-TCL1 mice as a possible reason for no additional effects of
CXCR4 hyperactivation on survival in the Eµ-Myc lymphoma model,
we first measured CXCR4 surface expression in the different
genotypes. Eµ-Myc lymphoma cells displayed significantly increased
CXCR4 surface expression compared to normal B cells and Eµ-TCL1
lymphoma cells (Supplementary Fig. S7a), indicating a potential link
between MYC and CXCR4 expression. To further explore the
association of MYC and CXCR4 expression, we analyzed patient
datasets and found a significant correlation ofMYCmRNA and IG-MYC
translocation status with CXCR4mRNA expression in B-cell lymphoma































































































































Fig. 3 CXCR4 hyperactivation accelerates TCL1-induced lymphomagenesis and dissemination in vivo. a Kaplan–Meier survival curves of the
indicated cohorts of mice (Eµ-TCL1, n= 18; Eµ-TCL1;CXCR4C1013G, n= 22). Median survival and P value of logrank (Mantel–Cox) test is shown. b Pie
charts depicting fractions of animals with overt lymphadenopathy in Eµ-TCL1 (n= 22) and Eµ-TCL1;CXCR4C1013G mice (n= 18). P value of Fisher’s
exact test is shown. c Representative images of H&E and immunohistochemistry of Eµ-TCL1 and Eµ-TCL1;CXCR4C1013G with manifest lymphoma
(scale bars spleen: overview= 1mm, detailed images: 200 µm, scale bars bone marrow: overview= 200 µm, detailed images= 20 µm).
d Representative images of H&E and immunohistochemistry of a Eµ-TCL1;CXCR4C1013G animal presenting with Ki67 positive Richter-like aggressive
lymphoma (scale bars: H&E overview= 200 µm, H&E detailed image= 50 µm, IHC detailed images= 100 µm). e Experimental setup and
quantification for ex vivo transwell migration of all splenocytes, CD5+ T cells and CD19+CD5+ cells toward 50 nM CXCL12 isolated from
genotypes as indicated (WT, n= 6; CXCR4C1013G, n= 5; Eµ-TCL1, n= 6; Eµ-TCL1;CXCR4C1013G, n= 6). Statistical analyses were performed with one-way
ANOVA with Tukey correction for multiple comparisons, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars indicate standard deviation (SD).
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sequencing on CD19+ lymphoma cells from Eµ-Myc and Eµ-Myc;
CXCR4C1013G and found that both groups displayed a highly similar
transcriptome dominated by the MYC signature, with only eight
pathways significantly altered in a gene set enrichment analysis
(Supplementary Fig. S8a, b, c). In line with MYC-induced CXCR4
expression, applying our defined signature of CXCR4 hyperactivation
did not show significant enrichment in the Eµ-Myc;CXCR4C1013G versus
Eµ-Myc (Supplementary Fig. S8d) compared to Eµ-TCL;CXCR4C1013G
versus Eµ-TCL1 (Supplementary Fig. S8e). In Eµ-TCL;CXCR4C1013G mice
the CXCR4 hyperactivation signature was highly and significantly
enriched compared to Eµ-TCL1 littermates. These findings indicate
that MYC might positively regulate CXCR4 transcript levels in B-cell


















































































































Fig. 4 CXCR4 hyperactivation does not accelerate MYC-driven B-cell lymphoma. a Outline of breeding scheme of CXCR4C1013G and Eµ-Myc
mice to generate double-transgenic Eµ-Myc;CXCR4C1013G mice. b Spleen weight of 1-month-old animals of genotypes as indicated (WT, n= 9;
CXCR4C1013G, n= 8; Eµ-Myc n= 12; Eµ-Myc;CXCR4C1013G, n= 6). c Representative images of H&E and immunohistochemistry of 1-month-old Eµ-
Myc and Eµ-Myc;CXCR4C1013G mice (scale bars: overview= 1mm, detailed images: 20 µm). d Spleen weight of Eµ-Myc (n= 9) and Eµ-Myc;
CXCR4C1013G (n= 13) mice with manifest lymphoma. e Bone marrow cell count of Eµ-Myc (n= 5) and Eµ-Myc;CXCR4C1013G (n= 7) mice with
manifest lymphoma. f Kaplan–Meier survival curves of the indicated cohorts of mice (Eµ-Myc, n= 15; Eµ-Myc;CXCR4C1013G, n= 17). Median
survival and P value of logrank (Mantel–Cox) test are shown. g Representative images of H&E and immunohistochemistry of Eµ-Myc and Eµ-
Myc;CXCR4C1013G mice with manifest lymphoma (scale bars spleen: overview= 1mm, detailed images: 20 µm, scale bars liver: overview=
1mm, detailed images= 20 µm). Statistical analyses were performed with Student’s t test or one-way ANOVA with Tukey correction for
multiple comparisons, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars indicate standard deviation (SD).
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We conclude that CXCR4 activation is an integrative hallmark of
aggressive MYC-driven lymphoma, and show that MYC translocation
and MYC expression correlate with increased CXCR4 expression.
Accordingly, CXCR4C1013G in the Eµ-Myc model did not further
potentiate the already high transcriptional activity mediated by a
MYC-CXCR4 axis and had no significant effect on lymphoma latency.
Co-activation of CXCR4 and TCL1 governs a distinct oncogenic
transcriptional program in B cells
To further investigate how enhanced CXCR4 activation promotes
B-cell lymphoproliferation in vivo, we isolated CD19+ B cells from
spleen and bone marrow of 6-week-old Eµ-TCL1 and Eµ-TCL1;
CXCR4C1013G mice and respective controls and performed whole-
transcriptome profiling (Fig. 5a). As expected, neither Eµ-TCL1 nor
Eµ-TCL1;CXCR4C1013G had monoclonal B-cell proliferation at this stage
detectable by transcriptomic clonality analysis (Supplementary
Fig. S9) [38–40]. Gene set enrichment analysis of curated pathways
in CXCR4C1013G, Eµ-TCL1, and Eµ-TCL1;CXCR4C1013G compared to WT
controls revealed an overlap of deregulated pathways (Fig. 5b).
Importantly, pathways associated with B-cell cancer biology and
inflammation were enriched and DNA repair pathways were
depleted in Eµ-TCL1 compared to WT B cells, confirming the pre-
malignant state of Eµ-TCL1 B cells (Supplementary Fig. S10a).
A subset of deregulated pathways were enriched specifically in
Eµ-TCL1;CXCR4C1013G B cells (Fig. 5b). Among those, pathways
involved in cell cycle progression (PLK1 pathway, G2M checkpoint,
cell cycle checkpoints) were enriched, whereas pathways including
p53 signaling and apoptosis (P53 pathway, P53 dependent G1 DNA
damage response, apoptosis) and immune response (interferon
gamma response) were depleted in Eµ-TCL1;CXCR4C1013G B cells.
Next, to gain further insight into the phenotypic differences and
disease acceleration caused by additional CXCR4 signaling, we
directly compared Eµ-TCL1 with Eµ-TCL1;CXCR4C1013G B cells.
Strikingly, we found that the transcriptome of Eµ-TCL1;CXCR4C1013G
B cells maintained a distinct profile even compared to Eµ-TCL1,
comprising enrichment of cell cycle progression and proliferation
pathways and depletion of p53-, apoptosis-, and immune
response-related pathways (Fig. 5c). Analyzing expression of
individual genes, we found 2140 differentially expressed genes
between pre-malignant B cells from Eµ-TCL1 vs. Eµ-TCL1;
CXCR4C1013G mice. In line with the gene set enrichment analysis,
cell cycle genes like cyclins (Ccne1), cyclin-dependent kinase
phosphatases (Cdc25b), mitotic regulators (Aurkb, Prc1, Hdac6,
Nek2, Mki67), DNA repair and DNA damage response genes (Brca2,
Fanca, Rad54l) were among the top differentially expressed genes.
Transcripts of well-established tumor suppressor genes (Klf6, CD82)
and positive regulators of apoptosis (Pmaip1) were found to be
suppressed in Eµ-TCL1;CXCR4C1013G (Fig. 5d). Remarkably, multiple
key components of the Plk1-Foxm1 pathway were among the top
upregulated genes, including Plk1, Foxm1 itself, the bona-fide
Foxm1 target Cdc25b, the Foxm1 deubiquitinating enzyme Usp5
involved in stabilization of Foxm1 protein [41], and Myb, which
forms a complex with Foxm1 and is required for its function.
To further support the finding that CXCR4 hyperactivation
potentiates oncogenic programs, we used the Cancer Gene Census
[42] and human B-cell lymphoma datasets [27, 28] for cross-species
validation. We calculated the overlap of DEG in Eµ-TCL1;CXCR4C1013G
vs. Eµ-TCL1 B cells with the Cancer Gene Census (Supplementary
Fig. S10b) and DLBCL driving genes in two large patient cohorts
(Supplementary Fig. S10c) and found that ten DEGs in our cohort
were identified in both DLBCL datasets [27, 28].
To further evaluate if the transcriptional program of patients with
Richter’s transformation resembles the transcriptomic changes
supported by enhanced CXCR4 signaling, we generated a gene
signature from CLL patient data with Richter’s transformation [43].
Strikingly, this “Richter-signature” enriched significantly only in Eµ-
TCL1;CXCR4C1013G, but not in Eµ-TCL1 or CXCR4C1013G B cells, showing
that key transcriptomic features of Richter’s transformation are
promoted by CXCR4 hyperactivation in cooperation with TCL1 (Fig. 5e
and Supplementary Fig. S10d). Finally, we stratified a cohort of CLL
patients using upregulated genes of the CXCR4C1013G vs. WT (CXCR4a)
and Eµ-TCL1;CXCR4C1013G vs Eµ-TCL1 signature. We found that patients
characterized by CXCR4a had significantly reduced time to treatment
(TTT) and patients characterized by the Eµ-TCL1;CXCR4C1013G vs Eµ-
TCL1 signature had significantly reduced TTT and overall survival
(Fig. 5f), further supporting the association of CXCR4 hyperactivation
with aggressive lymphoma biology.
DISCUSSION
In this study we co-expressed CXCR4C1013G with the B-cell
oncogenes TCL1 and MYC to investigate the effects of enhanced
CXCR4 signaling on B-cell leukemogenesis and lymphomagenesis.
Hyperactivated CXCR4 functioned as an oncogene cooperating
with TCL1 to accelerate CLL progression and development of
aggressive B-cell lymphoma.
CXCR4 expression has been implicated as an adverse prognostic
factor in DLBCL in retrospective analyses [14, 44]. However,
CXCR4 signaling activity is a highly dynamic and tightly regulated
process, which is not always adequately reflected by gene
expression alone [5]. Previous studies on CXCR4 gain-of-function
mutations focused on established Waldenström Macroglobulinemia
cell lines, as CXCR4 mutations are present in a third of patients with
this disease [45], thereby limiting conclusions to already transformed
cells [46, 47]. The role of CXCR4 in CLL has been thoroughly
investigated and it has become clear that the CXCR4-CXCL12 axis is
essential for CLL cells and their interaction with the microenviron-
ment, especially in response to BTK inhibition with ibrutinib [17, 25].
However, it was unclear how hyperactive CXCR4 signaling impacts
the development of CLL in vivo. Our work represents the first study
providing in vivo evidence that CXCR4 acts as an oncogene in B cells
by expressing a gain-of-function mutation together with known
B-cell oncogenes. Importantly, CXCR4C1013G provokes tremendous
transcriptomic and phenotypic changes in pre-malignant B cells. We
discovered an expansion of B1 B cells mediated by CXCR4C1013G,
indicating a susceptibility of hyperactivated CXCR4 signaling toward
mature B-cell neoplasms, as this fraction of B cells harbor the
potential for transformation into CLL and mantle cell lymphoma [48].
This susceptibility does not result in development of B-cell
neoplasms in the CXCR4C1013G mouse model alone [9] but requires
the context of additional oncogenic drivers, as shown in our studies.
In cooperation with the oncogene TCL1, CXCR4 hyperactivation
even favors development of aggressive B-cell lymphoma. Intrigu-
ingly, in CLL patients with Richter’s transformation mutations in
regulatory elements of CXCR4 have recently been discovered [43].
The transcriptional alterations induced by CXCR4 hyperactiva-
tion were consistent with CXCR4 function as indicated by
enrichment of curated pathway gene sets for chemokine signaling
and inflammation. Intriguingly, RNA sequencing also revealed
enhanced expression of Prdm1, a master regulator of plasma cell
proliferation and differentiation, which was found to be essential
for the survival of WM cells by regulating EZH2, a promising
therapeutic target in B-cell lymphoma [49, 50].
Of note, no mouse model with B-cell-specific CXCR4C1013G
expression exists, therefore additional, non-B-cell-intrinsic effects
of transgene expression in the microenvironment need to be
taken into consideration. It cannot be completely ruled out that
acceleration of lymphoma development might be partially
mediated by activated CXCR4 signaling in T cells or other cell
types of the tumor microenvironment known to express CXCR4.
Importantly, all transcriptomic data shown originate from CD19-
purified B cells. The finding that CXCR4 gene expression is highest
in B cells, and data that identified CXCR4 as a major regulator of
B-cell development and function [2, 10, 51, 52] further support
the notion of a B-cell-intrinsic effect of CXCR4 signaling in our
models. Furthermore, the migratory capacity ex vivo, without any
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support of the microenvironment, is enhanced most prominently
in CD19+CD5+ B cells of double-transgenic Eµ-TCL1;CXCR4C1013G
animals compared to controls, suggesting a direct collaboration of
TCL1 and CXCR4 in a specific subset of B cells. Of note, frequency of
CD4+ and CD8+ T cells in spleens of Eµ-TCL1 and Eµ-TCL1;
CXCR4C1013G did not differ significantly, which might suggest that
CXCR4 activation in T cells did not result in dramatically reduced T-
cell-mediated immune surveillance. Moreover, we could detect an
aggressive lymphoma phenotype in the histology of a subset of
mice as well as an enrichment of a patient-derived “Richter-
signature” in the transcriptomic program of pre-malignant Eµ-TCL1;
CXCR4C1013G B cells. This further indicates a B-cell-specific influence
of CXCR4 signaling toward a more aggressive lymphoma pheno-
type. In the light of recent findings linking active Akt signaling, a
downstream target of CXCR4, to Richter’s transformation [23], it
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Fig. 5 Co-activation of CXCR4 and TCL1 governs a distinct oncogenic transcriptional program in B cells. a Outline of experimental setup
for RNA sequencing of splenic and bone marrow pre-malignant B cells (WT, n= 5; CXCR4C1013G, n= 5; Eµ-TCL1, n= 5; Eµ-TCL1;CXCR4C1013G, n= 5).
b Venn diagram showing overlap of significantly enriched pathways (padj < 0.05) for curated gene sets listed in MsigDB [63, 64] of indicated
genotypes vs. WT B cells as determined by gene set enrichment analysis (GSEA). c GSEA of Eµ-TCL1;CXCR4C1013G vs. Eµ-TCL1 CD19+ B cells
showing normalized enrichment scores (NES) and false discovery rates (FDR) for curated gene sets listed in MsigDB [63, 64]. d Selection of
differentially expressed genes (DEG) with adjusted P value (padj) < 0.05 of Eµ-TCL1;CXCR4C1013G vs. Eµ-TCL1 CD19+ B cells. e GSEA showing
enrichment of a Richter’s transformation signature [43] in Eµ-TCL1;CXCR4C1013G B cells. f Kaplan–Meier plots of overall survival (OS) and time to
treatment (TTT) in a cohort of CLL patients, for patients with high vs. low enrichment of upregulated genes from CXCR4 signatures (CXCR4C1013G
vs. WT and Eµ-TCL1;CXCR4C1013G vs. Eµ-TCL1) (TTT CXCR4C1013G vs. WT, n= 105 high, n= 103 low; OS CXCR4C1013G vs. WT and Eµ-TCL1;CXCR4C1013G
vs. Eµ-TCL1, n= 105 in each group; TTT Eµ-TCL1;CXCR4C1013G vs. Eµ-TCL1, n= 104 in each group). P values of logrank (Mantel–Cox) test are shown.
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a contributing factor for the aggressive lymphoma phenotype in our
CXCR4 hyperactivation models.
Using the Eµ-Myc lymphoma model, we showed that CXCR4
transcript and surface expression is enhanced by oncogenic MYC.
MYC can bind and activate the CXCR4 promoter [53], but this
connection has not been explored in B-cell lymphoma so far.
Young Eµ-Myc;CXCR4C1013G animals presented with increased
spleen weight and more pronounced lymphoproliferation, which
did not translate in a reduction in overall survival. This could be
explained by a proportion of transformed B cells depending fully
on the MYC-oncogenic program and exponential tumor growth in
Eµ-Myc animals, which could mask biologically relevant effects of
additional CXCR4 hyperactivation as used in our experimental
approach. Furthermore, data from large B-cell lymphoma patient
datasets revealed a correlation of MYC and CXCR4 expression and
an increase of CXCR4 expression in patient samples with
translocation of MYC further supporting a regulation of CXCR4
by MYC in a B-cell oncogenic context.
The cooperation of CXCR4 and TCL1 was associated with
transcriptional activation of the Foxm1-Plk1 axis and proliferative
pathways [54]. PI3K and Akt might be the central signaling node
connecting CXCR4 and TCL1 signaling, resulting in inhibition of Foxo3
and de-repression of Foxm1 [55, 56]. In addition, PI3K/Akt
phosphorylates Plk1 that engages in a feed-forward loop with Foxm1
[57]. Both Plk1 and Foxm1 are promising therapeutic targets in B-cell
lymphoma [58, 59]. The Myb oncogene, which also displays increased
transcript expression in our Eµ-TCL1;CXCR4C1013G vs. Eµ-TCL1 RNA-Seq
data, is crucial for Foxm1 function [60, 61], and the Myb-Foxm1
interaction is required for proliferation in the germinal centers, a site
prone for malignant transformation of B cells [62].
In summary, we identified hyperactivated CXCR4 signaling as a
cooperative oncogenic factor in B-cell leukemogenesis and
lymphomagenesis associated with a distinct transcriptional
program. Hyperactivated CXCR4 resulted in a more disseminated
lymphoma phenotype and accelerated disease in TCL1-driven CLL,
while also favoring development of aggressive lymphoma. Next to
its role as a prognostic factor, CXCR4 activation might serve as
potential biomarker for novel targeted therapies, e.g., therapies
targeting the FOXM1-PLK1 axis and EZH2. These findings warrant
further investigation.
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